Spyre Therapeutics priced a $350 million offering to prepare for Phase III and advance SPY072 for hidradenitis suppurativa. Get the key funding details.
A Phase III trial will test MRD-guided giredestrant and CDK4/6 inhibitor use in early breast cancer. Explore the study design and its potential impact.
Gate Bioscience expands its Lilly deal for hard-to-drug proteins, with potential value above $870m. Read the latest on the ...
RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...
M in an IPO to advance its Treg pipeline toward Phase II, with Lilly as collaborator and investor. Read the offering details.
Equillium wins Australian clearance to begin EQ504's first-in-human Phase I trial. Read what the approval means for the biotech's clinical development.
Alector will receive $100M upfront as Genentech gains worldwide rights to its brain-penetrant GCase therapy for Parkinson’s.
Vaxcyte says its 31-valent VAX-31 vaccine met all primary endpoints in the OPUS-1 Phase III trial in adults aged 50 and older. Read the topline results.
Learn how AnnJi is advancing AJ201 into the Phase III ROMA-KD trial for SBMA in the US, a disease with no approved treatment. Read the latest update.
Italfarmaco and VeriSIM Life will combine AI and HDAC expertise in a preclinical drug discovery deal worth over USD 100 ...
Italfarmaco has licensed JCR’s brain-penetrating Hunter syndrome therapy for the US, Europe and Latin America. Read the details of the international deal.
The FDA approved Jaypirca for first-line CLL/SLL, following trial results showing an 80% reduction in progression risk. See ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results